Stelios Papadopoulos, a director at Exelixis, Inc. ($EXEL), sold shares on the open market three times over the past year, totaling nearly $6 million. His most recent sale occurred on November 12, 2025. These transactions rank him 1700th among nearly 12,000 insiders by sale value in our database, below the average of $8.6 million across about 6.4 sales per insider. Papadopoulos made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 26, 2026 | Ovid Therapeutics Inc. | $OVID | PAPADOPOULOS STELIOS | Not found | A | Employee Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 71,212,353 | 9999.99% | 0.09% |
| Nov. 12, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | S | Common Stock | 100000 | $43.55 | 1,189,228.0000 | 283,701,000 | 7.76% | 0.04% |
| May 29, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | A | Common Stock | 9812 | $0.00 | 1,289,228.0000 | 296,132,000 | 0.77% | 0.00% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | M | Common Stock | 15874 | $20.50 | 1,295,290.0000 | 296,132,000 | 1.24% | 0.01% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | S | Common Stock | 15874 | $44.35 | 1,279,416.0000 | 296,132,000 | 1.23% | 0.01% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | M | Option (right to buy) | 20634 | $0.00 | 0.0000 | 296,132,000 | 100.00% | 0.01% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | M | Option (right to buy) | 15874 | $0.00 | 0.0000 | 296,132,000 | 100.00% | 0.01% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | M | Common Stock | 20634 | $19.77 | 1,300,050.0000 | 296,132,000 | 1.61% | 0.01% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | S | Common Stock | 20634 | $44.35 | 1,279,416.0000 | 296,132,000 | 1.59% | 0.01% |
| March 3, 2025 | Ovid Therapeutics Inc. | $OVID | PAPADOPOULOS STELIOS | Not found | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 0 | 9999.99% | 0.00% |
| May 31, 2024 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | A | Common Stock | 18838 | $0.00 | 1,279,416.0000 | 321,464,000 | 1.49% | 0.01% |
| May 20, 2024 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | M | Common Stock | 11686 | $19.57 | 1,272,015.0000 | 321,464,000 | 0.93% | 0.00% |
| May 20, 2024 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | S | Common Stock | 11437 | $21.00 | 1,260,578.0000 | 321,464,000 | 0.90% | 0.00% |
| May 20, 2024 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | M | Option (right to buy) | 11686 | $0.00 | 0.0000 | 321,464,000 | 100.00% | 0.00% |
| June 1, 2023 | EXELIXIS, INC. | $EXEL | PAPADOPOULOS STELIOS | Director | A | Common Stock | 20718 | $0.00 | 1,260,329.0000 | 324,556,000 | 1.67% | 0.01% |